MX2022006071A - Composiciones y métodos para el tratamiento de enfermedades mediadas por ccr9 utilizando inhibidores de ccr9 y anticuerpos que bloquean anti-tnf-alfa. - Google Patents
Composiciones y métodos para el tratamiento de enfermedades mediadas por ccr9 utilizando inhibidores de ccr9 y anticuerpos que bloquean anti-tnf-alfa.Info
- Publication number
- MX2022006071A MX2022006071A MX2022006071A MX2022006071A MX2022006071A MX 2022006071 A MX2022006071 A MX 2022006071A MX 2022006071 A MX2022006071 A MX 2022006071A MX 2022006071 A MX2022006071 A MX 2022006071A MX 2022006071 A MX2022006071 A MX 2022006071A
- Authority
- MX
- Mexico
- Prior art keywords
- ccr9
- compositions
- methods
- tnf
- mediated diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En la presente descripción se proporcionan composiciones, métodos y kits para una enfermedad mediada por CCR9 en un mamífero que lo necesite. El método incluye administrar a un sujeto con una enfermedad mediada por CCR9 una terapia combinada que contiene una cantidad terapéuticamente eficaz de un compuesto inhibidor del receptor de quimiocina 9 (CCR9) y una cantidad terapéuticamente eficaz de un anticuerpo anti-TNF¿. También se proporciona en la presente descripción un kit que contiene el compuesto inhibidor de CCR9 y el anticuerpo anti-TNF¿.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962938795P | 2019-11-21 | 2019-11-21 | |
| US16/740,861 US10792360B1 (en) | 2019-11-21 | 2020-01-13 | Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies |
| US17/064,550 US20210154292A1 (en) | 2019-11-21 | 2020-10-06 | Compositions and Methods for Treating CCR9-Mediated Diseases using CCR9 Inhibitor and Anti-TNF-Alpha Blocking Antibodies |
| PCT/US2020/061569 WO2021102302A1 (en) | 2019-11-21 | 2020-11-20 | Compositions and methods for treating ccr9-mediated diseases using ccr9 inhibitor and anti-tnf-alpha blocking antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006071A true MX2022006071A (es) | 2022-08-02 |
Family
ID=75974977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006071A MX2022006071A (es) | 2019-11-21 | 2020-11-20 | Composiciones y métodos para el tratamiento de enfermedades mediadas por ccr9 utilizando inhibidores de ccr9 y anticuerpos que bloquean anti-tnf-alfa. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210154292A1 (es) |
| EP (1) | EP4061365A4 (es) |
| JP (1) | JP2023502267A (es) |
| KR (1) | KR20220103980A (es) |
| CN (1) | CN115209896A (es) |
| AU (1) | AU2020386066A1 (es) |
| BR (1) | BR112022009638A2 (es) |
| CA (1) | CA3159127A1 (es) |
| IL (1) | IL293133A (es) |
| MX (1) | MX2022006071A (es) |
| WO (1) | WO2021102302A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202203916A (zh) | 2020-03-31 | 2022-02-01 | 美商卡默森屈有限公司 | 使用ｃｃｒ９抑制劑及抗ｉｌ—２３阻斷抗體治療發炎性腸道疾病的組成物及方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04011465A (es) * | 2002-05-24 | 2005-02-14 | Millennium Pharm Inc | Inhibidores de ccr9 y metodos de uso de los mismos. |
| US8815887B2 (en) * | 2012-12-04 | 2014-08-26 | Millenium Pharmaceuticals, Inc. | Prophylactic or therapeutic method for Sjogren's syndrome |
| EA032559B1 (ru) * | 2014-04-04 | 2019-06-28 | Пфайзер Инк. | Бициклические аннелированные гетероарильные или арильные соединения и их применение в качестве ингибиторов irak4 |
| JP6954834B2 (ja) * | 2014-10-06 | 2021-10-27 | ケモセントリックス，インコーポレイティド | ＣＣケモカイン受容体９（ＣＣＲ９）の阻害剤と抗α４β７インテグリン遮断抗体の併用療法 |
| EP3554541B1 (en) * | 2016-12-14 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| US10792360B1 (en) * | 2019-11-21 | 2020-10-06 | Chemocentryx, Inc. | Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies |
| TW202203916A (zh) * | 2020-03-31 | 2022-02-01 | 美商卡默森屈有限公司 | 使用ｃｃｒ９抑制劑及抗ｉｌ—２３阻斷抗體治療發炎性腸道疾病的組成物及方法 |
-
2020
- 2020-10-06 US US17/064,550 patent/US20210154292A1/en not_active Abandoned
- 2020-11-20 KR KR1020227019228A patent/KR20220103980A/ko unknown
- 2020-11-20 IL IL293133A patent/IL293133A/en unknown
- 2020-11-20 AU AU2020386066A patent/AU2020386066A1/en active Pending
- 2020-11-20 EP EP20890027.4A patent/EP4061365A4/en active Pending
- 2020-11-20 WO PCT/US2020/061569 patent/WO2021102302A1/en active Application Filing
- 2020-11-20 BR BR112022009638A patent/BR112022009638A2/pt unknown
- 2020-11-20 CN CN202080094015.2A patent/CN115209896A/zh active Pending
- 2020-11-20 MX MX2022006071A patent/MX2022006071A/es unknown
- 2020-11-20 JP JP2022529553A patent/JP2023502267A/ja not_active Withdrawn
- 2020-11-20 CA CA3159127A patent/CA3159127A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3159127A1 (en) | 2021-05-27 |
| CN115209896A (zh) | 2022-10-18 |
| US20210154292A1 (en) | 2021-05-27 |
| JP2023502267A (ja) | 2023-01-23 |
| AU2020386066A1 (en) | 2022-06-09 |
| KR20220103980A (ko) | 2022-07-25 |
| WO2021102302A1 (en) | 2021-05-27 |
| EP4061365A1 (en) | 2022-09-28 |
| EP4061365A4 (en) | 2023-11-29 |
| BR112022009638A2 (pt) | 2022-08-09 |
| IL293133A (en) | 2022-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020008445A (es) | Metodos para tratar el cancer con anticuerpos anti-pd-1. | |
| MX2022015968A (es) | Terapia con anticuerpos anti ccr8: biomarcadores y terapias combinadas. | |
| NO20051048L (no) | Terapeutisk humant anti-IL-1R1 monoklonalt antistoff | |
| SG148143A1 (en) | Antagonist anti-cd40 monoclonal antibodies and methods for their use | |
| AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| EA201792522A1 (ru) | Лечение злокачественной опухоли с помощью комбинированной блокады сигнальных путей pd-1 и cxcr4 | |
| CY1111011T1 (el) | Χρηση των anti-cd40 μονοκλωνικων αντισωματων για την θεραπευτικη αγωγη πολλαπλου μυελωματος | |
| ATE489403T1 (de) | Humane antikörper gegen cd40 | |
| ATE367816T1 (de) | Verwendung von niedrigen dosen estrogen in kombination mit immunotherapeutischen verbindungen zur behandlung von immunkrankheiten | |
| EA201490957A1 (ru) | Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела | |
| NO985150L (no) | Antigenbindingsfragmenter som spesifikt detekterer cancerceller, nukleotider som koder fragmentene samt anvendelse derav for profylakse og deteksjon av cancere | |
| MX2022001403A (es) | Metodos de administracion de anticuerpos anti-siglec-8 y corticosteroides. | |
| EA202092162A1 (ru) | Антитела против cxcl13 для лечения аутоиммунных заболеваний и рака | |
| EP4268820A3 (en) | Combination therapy of c-c chemokine receptor-9 (ccr9) inhibitors and anti-alpha4beta7 integrin blocking antibodies for the treatment of inflammatory bowel disease | |
| CO2022015033A2 (es) | Composiciones y métodos para tratar la enfermedad intestinal inflamatoria mediante el uso de inhibidor de ccr9 y anticuerpos bloqueadores anti-il-23 | |
| MX2022006071A (es) | Composiciones y métodos para el tratamiento de enfermedades mediadas por ccr9 utilizando inhibidores de ccr9 y anticuerpos que bloquean anti-tnf-alfa. | |
| JP2023055904A5 (es) | ||
| MX2022007521A (es) | Anticuerpos contra la integrina alfa 11 beta 1. | |
| CA2364026A1 (en) | Anti-tnf.alpha. antibodies in therapy of asthma | |
| MX2021006210A (es) | Metodos para diagnosticar y/o tratar una hepatopatia, nefropatia o neumopatia aguda o cronica. | |
| MX2022003762A (es) | Molécula de unión específica para el factor inhibidor de la leucemia (lif) y uso de la misma. | |
| MX2022006728A (es) | Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario. | |
| MX2021013222A (es) | Metodos para tratar el cancer con un anticuerpo anti-pd-l1. | |
| WO2023147489A3 (en) | Anti-musk antibodies for use in treating neuromuscular disorders | |
| AU2020271352A8 (en) | Combinations of anti-ILDR2 antibodies and PD-1 antagonists |